Background: Patients with Philadelphia-negative chronic myeloproliferative neoplasms (MPN) typically incur high rates of infections and both drugs and comorbidities may modulate infection risk. Objectives: The present study aims to assess the effect of immunosuppressive agents on clinical outcomes of MPN patients affected by the coronavirus disease 2019 (COVID-19). Design: This is an observational study. Methods: We specifically searched and analyzed MPN patients collected by EPICOVIDEHA online registry, which includes individuals with hematological malignancies diagnosed with COVID-19 since February 2020. Results: Overall, 398 patients with MPN were observed for a median of 76 days [interquartile range (IQR): 19–197] after detection of SARS-CoV2 infection. Median age was 69 years (IQR: 58–77) and 183 individuals (46%) had myelofibrosis (MF). Overall, 121 patients (30%) of the whole cohort received immunosuppressive therapies including steroids, immunomodulatory drugs, or JAK inhibitors. Hospitalization and consecutive admission to intensive care unit was required in 216 (54%) and 53 patients (13%), respectively. Risk factors for hospital admission were identified by multivariable logistic regression and include exposure to immunosuppressive therapies [odds ratio (OR): 2.186; 95% confidence interval (CI): 1.357–3.519], age ⩾70 years, and comorbidities. The fatality rate was 22% overall and the risk of death was independently increased by age ⩾70 years [hazard ratio (HR): 2.191; 95% CI: 1.363–3.521], previous comorbidities, and exposure to immunosuppressive therapies before the infection (HR: 2.143; 95% CI: 1.363–3.521). Conclusion: COVID-19 infection led to a particularly dismal outcome in MPN patients receiving immunosuppressive agents or reporting multiple comorbidities. Therefore, specific preventive strategies need to be tailored for such individuals. Plain language summary EPICOVIDEHA registry reports inferior outcomes of COVID-19 in patients with Philadelphia-negative chronic myeloproliferative neoplasms receiving immunosuppressive therapies. Patients with Philadelphia-negative chronic myeloproliferative neoplasms (MPN) incur high rates of infections during the course of their disease. The present study was aimed at assessing which patient characteristics predicted a worse outcome of SARS-COV-2 infection in individuals with MPN. To pursue this objective, the researchers analyzed the data collected by EPICOVIDEHA, an international online registry, which includes individuals with hematological malignancies diagnosed with COVID-19 since February 2020. The database provided clinical data of 398 patients with MPN incurring COVID-19: Patients were mostly elderly (median age was 69 years); Forty-six percent of them were affected by myelofibrosis, which is the most severe MPN; Moreover, 32% were receiving immunosuppressive therapies (JAK inhibitors, such as ruxolitinib, steroids, or immunomodulatory IMID drugs, such as thalidomide) before COVID-19. Hospitalization was required in 54% of the patients, and the risk of being hospitalized for severe COVID-19 was independently predicted by Older age; Comorbidities; Exposure to immunosuppressive therapies. Overall, 22% of MPN patients deceased soon after COVID-19 and the risk of death was independently increased over twofold by Older age; Comorbidities; Exposure to immunosuppressive therapies before the infection. In conclusion, COVID-19 infection led to a particularly dismal outcome in MPN patients receiving immunosuppressive agents, including JAK inhibitors, or reporting multiple comorbidities. Therefore, specific preventive strategies need to be tailored for such individuals.
Authors: Ola Blennow; Jon Salmanton‐García; Piotr Nowak; Federico Itri; +64 Authors
Ola Blennow; Jon Salmanton‐García; Piotr Nowak; Federico Itri; Jaap Van Doesum; Alberto López‐García; Francesca Farina; Ozren Jaksic; László Imre Pinczés; Yavuz M. Bilgin; Iker Falces‐Romero; Moraima Jiménez; Irati Ormazabal‐Vélez; Barbora Weinbergerová; Rémy Duléry; Zlate Stojanoski; Tobias Lahmer; Noemí Fernández; José‐Ángel Hernández‐Rivas; Verena Petzer; Nick De Jonge; Andreas Glenthøj; Cristina De Ramón; Monika M. Biernat; Nicola Fracchiolla; Avinash Aujayeb; Jens Van Praet; Martin Schönlein; Gustavo‐Adolfo Méndez; Chiara Cattaneo; Anna Guidetti; Mariarita Sciumè; Emanuele Ammatuna; Raul Cordoba; Nicole García‐Poutón; Stefanie Gräfe; Alba Cabirta; Dominik Wolf; Anna Nordlander; Ramón García‐Sanz; Mario Delia; Caroline Berg Venemyr; Clara Brones; Roberta Di Blasi; Elizabeth De Kort; Stef Meers; Sylvain Lamure; Laura Serrano; Maria Merelli; Nicola Coppola; Rui Bergantim; Caroline Besson; Milena Kohn; Jessica Petiti; Carolina Garcia‐Vidal; Michelina Dargenio; François Danion; Marina Machado; Rebeca Bailén‐Almorox; Martin Hoenigl; Giulia Dragonetti; Louis Yi Ann Chai; Chi Shan Kho; Matteo Bonanni; Raphaël Liévin; Francesco Marchesi; Oliver A. Cornely; Livio Pagano;
descriptionPublicationkeyboard_double_arrow_right Article , Other literature type 2021 France, Belgium, France, Italy, France, Italy, France, Slovenia, Germany, Italy, Netherlands Elsevier BV
Authors: Paul Hofman; M. Ilié; E. Chamorey; P. Brest; +76 Authors
Paul Hofman; M. Ilié; E. Chamorey; P. Brest; R. Schiappa; V. Nakache; M. Antoine; M. Barberis; H. Begueret; F. Bibeau; C. Bonnetaud; P. Boström; P. Brousset; Lukas Bubendorf; Lina Carvalho; G. Cathomas; Aurélie Cazes; L. Chalabreysse; M.-P. Chenard; M.-C. Copin; J.-F. Côté; D. Damotte; L. de Leval; P. Delongova; V. Thomas de Montpreville; A. De Muret; A. Dema; W. Dietmaier; M. Evert; Aurelie Fabre; Fabien Forest; A. Foulet; S. Garcia; M. Garcia-Martos; L. Gibault; G. Gorkiewicz; Danny Jonigk; John R. Gosney; A. Hofman; Izidor Kern; Keith M. Kerr; M. Kossai; Mark Kriegsmann; S. Lassalle; E. Long-Mira; A. Lupo; A. Mamilos; R. Matěj; J. Meilleroux; Cristian Ortiz-Villalón; L. Panico; A. Panizo; Mauro Papotti; Patrick Pauwels; Giuseppe Pelosi; Frédérique Penault-Llorca; O. Pop; N. Poté; S.R.Y. Cajal; J.-C. Sabourin; I. Salmon; M. Sajin; S. Savic-Prince; Hans-Ulrich Schildhaus; Peter Schirmacher; I. Serre; E. Shaw; D. Sizaret; A. Stenzinger; J. Stojsic; Erik Thunnissen; Wim Timens; G. Troncone; C. Werlein; H. Wolff; J.-P. Berthet; J. Benzaquen; C.-H. Marquette; Véronique Hofman; F. Calabrese;
Background This study evaluated the consequences in Europe of the COVID-19 outbreak on pathology laboratories orientated toward the diagnosis of thoracic diseases. Materials and methods A survey was sent to 71 pathology laboratories from 21 European countries. The questionnaire requested information concerning the organization of biosafety, the clinical and molecular pathology, the biobanking, the workload, the associated research into COVID-19, and the organization of education and training during the COVID-19 crisis, from 15 March to 31 May 2020, compared with the same period in 2019. Results Questionnaires were returned from 53/71 (75%) laboratories from 18 European countries. The biosafety procedures were heterogeneous. The workload in clinical and molecular pathology decreased dramatically by 31% (range, 3%-55%) and 26% (range, 7%-62%), respectively. According to the professional category, between 28% and 41% of the staff members were not present in the laboratories but did teleworking. A total of 70% of the laboratories developed virtual meetings for the training of residents and junior pathologists. During the period of study, none of the staff members with confirmed COVID-19 became infected as a result of handling samples. Conclusions The COVID-19 pandemic has had a strong impact on most of the European pathology laboratories included in this study. Urgent implementation of several changes to the organization of most of these laboratories, notably to better harmonize biosafety procedures, was noted at the onset of the pandemic and maintained in the event of a new wave of infection occurring in Europe. Highlights • Biosafety measures used in the first wave of the COVID-19 crisis were heterogeneous in 53 European pathology laboratories. • A dramatic decrease of the workload in pathology laboratories was noted. • No case of healthcare workers contaminated with SARS-CoV-2 associated with samples handling was identified.
Darko Antic; Natasa Milic; Thomas Chatzikonstantinou; Lydia Scarfò; Vladimir Otasevic; Nina Rajovic; David Allsup; Alejandro Alonso Cabrero; Martin Andres; Monica Baile Gonzales; Antonella Capasso; Rosa Collado; Raul Cordoba; Carolina Cuéllar-García; Juan Gonzalo Correa; Lorenzo De Paoli; Maria Rosaria De Paolis; Giovanni Del Poeta; Maria Dimou; Michael Doubek; Maria Efstathopoulou; Shaimaa El-Ashwah; Alicia Enrico; Blanca Espinet; Lucia Farina; Angela Ferrari; Myriam Foglietta; Alberto Lopez-Garcia; José A. García-Marco; Rocío García-Serra; Massimo Gentile; Eva Gimeno; Maria Gomes da Silva; Odit Gutwein; Yervand K. Hakobyan; Yair Herishanu; José Ángel Hernández-Rivas; Tobias Herold; Gilad Itchaki; Ozren Jaksic; Ann Janssens; Olga B. Kalashnikova; Elżbieta Kalicińska; Arnon P. Kater; Sabina Kersting; Maya Koren-Michowitz; Jorge Labrador; Deepesh Lad; Luca Laurenti; Alberto Fresa; Mark-David Levin; Carlota Mayor Bastida; Lara Malerba; Roberto Marasca; Monia Marchetti; Juan Marquet; Biljana Mihaljevic; Ivana Milosevic; Fatima Mirás; Marta Morawska; Marina Motta; Talha Munir; Roberta Murru; Raquel Nunes; Jacopo Olivieri; Miguel Arturo Pavlovsky; Inga Piskunova; Viola Maria Popov; Francesca Maria Quaglia; Giulia Quaresmini; Gianluigi Reda; Gian Matteo Rigolin; Amit Shrestha; Martin Šimkovič; Svetlana Smirnova; Martin Špaček; Paolo Sportoletti; Oana Stanca; Niki Stavroyianni; Doreen Te Raa; Kristina Tomic; Sanne Tonino; Livio Trentin; Ellen Van Der Spek; Michel van Gelder; Marzia Varettoni; Andrea Visentin; Candida Vitale; Vojin Vukovic; Ewa Wasik-Szczepanek; Tomasz Wróbel; Lucrecia Yáñez San Segundo; Mohamed Yassin; Marta Coscia; Alessandro Rambaldi; Emili Montserrat; Robin Foà; Antonio Cuneo; Marc Carrier; Paolo Ghia; Kostas Stamatopoulos;
Abstract Background Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to COVID-19 related poor outcomes, including thrombosis and death, due to the advanced age, the presence of comorbidities, and the disease and treatment-related immune deficiency. The aim of this study was to assess the risk of thrombosis and bleeding in patients with CLL affected by severe COVID-19. Methods This is a retrospective multicenter study conducted by ERIC, the European Research Initiative on CLL, including patients from 79 centers across 22 countries. Data collection was conducted between April and May 2021. The COVID-19 diagnosis was confirmed by the real-time polymerase chain reaction (RT-PCR) assay for SARS-CoV-2 on nasal or pharyngeal swabs. Severe cases of COVID-19 were defined by hospitalization and the need of oxygen or admission into ICU. Development and type of thrombotic events, presence and severity of bleeding complications were reported during treatment for COVID-19. Bleeding events were classified using ISTH definition. STROBE recommendations were used in order to enhance reporting. Results A total of 793 patients from 79 centers were included in the study with 593 being hospitalized (74.8%). Among these, 511 were defined as having severe COVID: 162 were admitted to the ICU while 349 received oxygen supplementation outside the ICU. Most patients (90.5%) were receiving thromboprophylaxis. During COVID-19 treatment, 11.1% developed a thromboembolic event, while 5.0% experienced bleeding. Thrombosis developed in 21.6% of patients who were not receiving thromboprophylaxis, in contrast to 10.6% of patients who were on thromboprophylaxis. Bleeding episodes were more frequent in patients receiving intermediate/therapeutic versus prophylactic doses of low-molecular-weight heparin (LWMH) (8.1% vs. 3.8%, respectively) and in elderly. In multivariate analysis, peak D-dimer level and C-reactive protein to albumin ratio were poor prognostic factors for thrombosis occurrence (OR = 1.022, 95%CI 1.007‒1.038 and OR = 1.025, 95%CI 1.001‒1.051, respectively), while thromboprophylaxis use was protective (OR = 0.199, 95%CI 0.061‒0.645). Age and LMWH intermediate/therapeutic dose administration were prognostic factors in multivariate model for bleeding (OR = 1.062, 95%CI 1.017–1.109 and OR = 2.438, 95%CI 1.023–5.813, respectively). Conclusions Patients with CLL affected by severe COVID-19 are at a high risk of thrombosis if thromboprophylaxis is not used, but also at increased risk of bleeding under the LMWH intermediate/therapeutic dose administration.
Fabian Eibensteiner; Valentin Ritschl; Tanja Stamm; Asil Cetin; Claus Peter Schmitt; Gema Ariceta; Sevcan A. Bakkaloglu; Augustina Jankauskiene; Günter Klaus; Fabio Paglialonga; Alberto Edefonti; Bruno Ranchin; Rukshana Shroff; Constantinos J. Stefanidis; Johan Vandewalle; Enrico Verrina; Karel Vondrak; Aleksandra Zurowska; Seth L. Alper; Christoph Aufricht;
ObjectivesIn a previously published Delphi exercise the European Pediatric Dialysis Working Group (EPDWG) reported widely variable counteractive responses to COVID-19 during the first week of statutory public curfews in 12 European countries with case loads of 4–680 infected patients per million. To better understand these wide variations, we assessed different factors affecting countermeasure implementation rates and applied the capability, opportunity, motivation model of behaviour to describe their determinants.DesignWe undertook this international mixed methods study of increased depth and breadth to obtain more complete data and to better understand the resulting complex evidence.SettingThis study was conducted in 14 paediatric nephrology centres across 12 European countries during the COVID-19 pandemic.ParticipantsThe 14 participants were paediatric nephrologists and EPDWG members from 12 European centres.Main outcome measures52 countermeasures clustered into eight response domains (access control, patient testing, personnel testing, personal protective equipment policy, patient cohorting, personnel cohorting, suspension of routine care, remote work) were categorised by implementation status, drivers (expert opinion, hospital regulations) and resource dependency. Governmental strictness and media attitude were independently assessed for each country and correlated with relevant countermeasure implementation factors.ResultsImplementation rates varied widely among response domains (median 49.5%, range 20%–71%) and centres (median 46%, range 31%–62%). Case loads were insufficient to explain response rate variability. Increasing case loads resulted in shifts from expert opinion-based to hospital regulation-based decisions to implement additional countermeasures despite increased resource dependency. Higher governmental strictness and positive media attitude towards countermeasure implementation were associated with higher implementation rates.ConclusionsCOVID-19 countermeasure implementation by paediatric tertiary care centres did not reflect case loads but rather reflected heterogeneity of local rules and of perceived resources. These data highlight the need of ongoing reassessment of current practices, facilitating rapid change in ‘institutional behavior’ in response to emerging evidence of countermeasure efficacy.
descriptionPublicationkeyboard_double_arrow_right Article 2021 Denmark, Belgium, Switzerland, Netherlands European Respiratory Society (ERS)
Authors: June K. Marthin; Jane S. Lucas; Mieke Boon; Carmen Casaulta; +20 Authors
June K. Marthin; Jane S. Lucas; Mieke Boon; Carmen Casaulta; Suzanne Crowley; Damien M.S. Destouches; Ernst Eber; Amparo Escribano; Eric G. Haarman; Claire Hogg; Bernard Maitre; Gemma Marsh; Vendula Martinu; Antonio Moreno-Galdó; Huda Mussaffi; Heymut Omran; Petr Pohunek; Bernhard Rindlisbacher; Phil Robinson; Deborah Snijders; Woolf T. Walker; Panayiotis K. Yiallouros; Helle Krogh Johansen; Kim G. Nielsen;
Introduction In primary ciliary dyskinesia (PCD) impaired mucociliary clearance leads to recurrent airway infections and progressive lung destruction, and concern over chronic airway infection and patient-to-patient transmission is considerable. So far, there has been no defined consensus on how to control infection across centres caring for patients with PCD. Within the BEAT-PCD network, COST Action and ERS CRC together with the ERN-Lung PCD core a first initiative has now been taken towards creating such a consensus statement. Methods A multidisciplinary international PCD expert panel was set up to create a consensus statement for infection prevention and control (IP&C) for PCD, covering diagnostic microbiology, infection prevention for specific pathogens considered indicated for treatment and segregation aspects. Using a modified Delphi process, consensus to a statement demanded at least 80% agreement within the PCD expert panel group. Patient organisation representatives were involved throughout the process. Results We present a consensus statement on 20 IP&C statements for PCD including suggested actions for microbiological identification, indications for treatment of Pseudomonas aeruginosa, Burkholderia cepacia and nontuberculous mycobacteria and suggested segregation aspects aimed to minimise patient-to-patient transmission of infections whether in-hospital, in PCD clinics or wards, or out of hospital at meetings between people with PCD. The statement also includes segregation aspects adapted to the current coronavirus disease 2019 (COVID-19) pandemic. Conclusion The first ever international consensus statement on IP&C intended specifically for PCD is presented and is targeted at clinicians managing paediatric and adult patients with PCD, microbiologists, patient organisations and not least the patients and their families. For the first time ever, an international consensus statement for infection prevention and control in PCD is presented. A total of 20 statements were developed in a collaboration of BEAT-PCD, COST Action, ERS CRC and ERN-LUNG PCD Core Network. https://bit.ly/3yuahKt
appsOther research productkeyboard_double_arrow_right Other ORP type 2020 Catalan; Valencian Servei Català de la Salut
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Mesures addicionals; Contenció; Brot Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Medidas adicionales; Contención; Brote Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Additional measures; Containment; Outbreak Informació adreçada a la població de diferents municipis de la comarca del Segrià de les mesures de seguretat que han de prendre pel nou brot de coronavirus COVID-19. Información dirigida a la población de diferentes municipios de la comarca del Segrià de las medidas de seguridad que deben tomar por el nuevo brote de coronavirus COVID-19. Information aimed at the population of different municipalities in the country of Segrià of the security measures to be taken for the new outbreak of coronavirus COVID-19.
descriptionPublicationkeyboard_double_arrow_right Other literature type , Article 2022 Netherlands, Turkey, Italy, Denmark, Italy, Turkey, France, Croatia, Belgium, Netherlands, Hungary MDPI AG
Authors: Chiara Cattaneo; Jon Salmanton-García; Francesco Marchesi; Shaimaa El-Ashwah; +72 Authors
Chiara Cattaneo; Jon Salmanton-García; Francesco Marchesi; Shaimaa El-Ashwah; Federico Itri; Barbora Weinbergerová; Maria Gomes Da Silva; Michelina Dargenio; Julio Dávila-Valls; Sonia Martín-Pérez; Francesca Farina; Jaap Van Doesum; Toni Valković; Caroline Besson; Christian Bjørn Poulsen; Alberto López-García; Pavel Žák; Martin Schönlein; Klára Piukovics; Ozren Jaksic; Alba Cabirta; Natasha Ali; Uluhan Sili; Nicola Fracchiolla; Giulia Dragonetti; Tatjana Adžić-Vukičević; Monia Marchetti; Marina Machado; Andreas Glenthøj; Olimpia Finizio; Fatih Demirkan; Ola Blennow; Maria Chiara Tisi; Ali S. Omrani; Milan Navrátil; Zdeněk Ráčil; Jan Novák; Gabriele Magliano; Moraima Jiménez; Carolina Garcia-Vidal; Nurettin Erben; Maria Ilaria Del Principe; Caterina Buquicchio; Rui Bergantim; Josip Batinić; Murtadha Al-Khabori; Luisa Verga; Tomáš Szotkowski; Michail Samarkos; Irati Ormazabal-Vélez; Stef Meers; Johan Maertens; László Imre Pinczés; Martin Hoenigl; Ľuboš Drgoňa; Annarosa Cuccaro; Yavuz M. Bilgin; Avinash Aujayeb; Laman Rahimli; Stefanie Gräfe; Mariarita Sciumè; Miloš Mladenović; Gökçe Melis Çolak; Maria Vittoria Sacchi; Anna Nordlander; Caroline Berg Venemyr; Michaela Hanáková; Nicole García-Poutón; Ziad Emarah; Giovanni Paolo Maria Zambrotta; Raquel Nunes Rodrigues; Raul Cordoba; Gustavo-Adolfo Méndez; Monika M. Biernat; Oliver A. Cornely; Livio Pagano;
Simple Summary Patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 are an even greater challenge for hematologists. To better clarify their outcome, we describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Overall, 343 (76.2%) patients received treatment for HM, and an overall response rate was observed in 140 (40.8%) patients after the first line of treatment. Thirty-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004). Statistical analysis showed that, together with age, severe/critical COVID-19, >= 2 comorbidities, lack of HM treatment was an independent risk factors for mortality. These observations suggest the importance of HM treatment in these patients; therefore, it should be delivered as soon as possible for patients requiring immediate therapy. Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p = 2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.
descriptionPublicationkeyboard_double_arrow_right Article 2021 Germany, Denmark, Spain, France, Spain, Norway European Centre for Disease Control and Prevention (ECDC)
Authors: Kimberley S. M. Benschop; Jan Albert; Andrés Antón; Cristina Andres; +76 Authors
Kimberley S. M. Benschop; Jan Albert; Andrés Antón; Cristina Andres; Maitane Aranzamendi; Brynja Armannsdottir; Jean-Luc Bailly; Fausto Baldanti; Guðrún Erna Baldvinsdóttir; Stuart Beard; Natasa Berginc; Sindy Böttcher; Soile Blomqvist; L. Bubba; Cristina Calvo; María Cabrerizo; Annalisa Cavallero; Cristina Celma; Ferruccio Ceriotti; Inês Costa; Simon Cottrell; Margarita Del Cuerpo; Jonathan Dean; Jennifer L. Dembinski; Sabine Diedrich; Javier Díez-Domingo; DagnyHaug Dorenberg; Erwin Duizer; Robert Dyrdak; Diana Fanti; Agnes Farkas; Susan Feeney; Jacky Flipse; Cillian De Gascun; Cristina Galli; Irina Georgieva; Laura Gifford; Raquel Guiomar; Mario Hönemann; Niina Ikonen; Marion Jeannoel; Laurence Josset; Kathrin Keeren; F. Xavier López-Labrador; Melanie Maier; James McKenna; Adam Meijer; Beatriz Mengual-Chuliá; Sofie Midgley; Audrey Mirand; Milagrosa Montes; Catherine Moore; Ursula Morley; Jean-Luc Murk; Lubomira Nikolaeva-Glomb; Sanela Numanovic; Massimo Oggioni; Paula Palminha; Elena Pariani; Laura Pellegrinelli; Antonio Piralla; Corinna Pietsch; Luis Pineiro; Nuria Rabella; Petra Rainetova; Sara Colonia Uceda Renteria; María Pilar Romero; Marijke Reynders; Lieuwe Roorda; Carita Savolainen-Kopra; Isabelle Schuffenecker; Aysa Soynova; Caroline Ma Swanink; Tina Uršič; Jaco J. Verweij; Jorgina Vila; Tytti Vuorinen; Peter Simmonds; Thea Kølsen Fischer; Heli Harvala;
Acute flaccid myelitis; Enterovirus D68; Surveillance Mielitis flàcida aguda; Enterovirus D68; Vigilància Mielitis flácida aguda; Enterovirus D68; Vigilancia We report a rapid increase in enterovirus D68 (EV-D68) infections, with 139 cases reported from eight European countries between 31 July and 14 October 2021. This upsurge is in line with the seasonality of EV-D68 and was presumably stimulated by the widespread reopening after COVID-19 lockdown. Most cases were identified in September, but more are to be expected in the coming months. Reinforcement of clinical awareness, diagnostic capacities and surveillance of EV-D68 is urgently needed in Europe.